ClinicaliQ Trial Snapshot
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) — Recruiting • Phase II • NCT06997588.
- Alpelisib (a targeted drug) tested in children and adults with PIK3CA gene mutations causing abnormal tissue overgrowth.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spectrum (PROS). Conditions: PIK3CA-related Overgrowth Spectrum (PROS) Interventions: Alpelisib Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 104 participants